Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
01:47pm, Thursday, 26'th Mar 2026
Hypertriglyceridemia is a condition characterized by abnormally high levels of triglycerides (fats) in the blood.
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106
11:27am, Thursday, 26'th Mar 2026
Ionis Pharmaceuticals (NASDAQ:IONS) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently t
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS
05:56am, Thursday, 26'th Mar 2026
DAVENPORT and Co LLC increased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 248.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exc
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
11:45am, Tuesday, 24'th Mar 2026
IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
07:00am, Monday, 23'rd Mar 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application
Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative
09:13am, Friday, 20'th Mar 2026
Ionis Pharmaceuticals (IONS) projects $2B+ peak revenue for Olezarsen, but I believe this is highly conservative given the U.S. addressable market. Olezarsen demonstrated a 72% reduction in triglyceri
Elizabeth Hougen Sells 215,048 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
04:26am, Friday, 20'th Mar 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Elizabeth Hougen sold 215,048 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
04:22pm, Tuesday, 17'th Mar 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Th
Algert Global LLC Grows Position in Ionis Pharmaceuticals, Inc. $IONS
03:27am, Sunday, 15'th Mar 2026
Algert Global LLC grew its position in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 562.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commissio
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
04:12pm, Wednesday, 11'th Mar 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
05:57pm, Monday, 09'th Mar 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Ionis announces changes to Board of Directors
07:00am, Monday, 09'th Mar 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retirin
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of “Moderate Buy” from Analysts
02:22am, Monday, 09'th Mar 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, MarketBeat.com repor
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $1,596,416.40 in Stock
04:52am, Sunday, 08'th Mar 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Shannon Devers sold 20,106 shares of the company's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average
